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Abstract
We report the restoration of euglycaemia in chemically induced diabetic C57BL/6 mice and spontaneously diabetic Non Obese
Diabetic (NOD) mice by intravenous systemic administration of a single-stranded adeno-associated virus (ssAAV2/8) codon
optimised (co) vector encoding furin cleavable human proinsulin under a liver-specific promoter. There were no immunological
barriers to efficacy of insulin gene therapy in chemically induced C57BL/6 mice, which enjoyed long-lasting correction of
hyperglycaemia after therapy, up to 250 days. Euglycaemia was also restored in spontaneously diabetic NOD mice, although these
mice required a 7–10-fold higher dose of vector to achieve similar efficacy as the C57BL/6 mice and the immunodeficient NODscid
mice. We detected CD8+ T cell reactivity to insulin and mild inflammatory infiltration in the livers of gene therapy recipient NOD
mice, neither of which were observed in the treated C57BL/6 mice. Efficacy of the gene therapy in NOD mice was partially
improved by targeting the immune system with anti-CD4 antibody treatment, while transfer of NODmouse AAV2/8-reactive serum
to recipients prevented successful restoration of euglycaemia in AAV2/8-HLP-hINSco-treated NODscid mice. Our data indicate that
both immune cells and antibodies form a barrier to successful restoration of euglycaemia in autoimmune diabetic recipient mice with
insulin gene therapy, but that this barrier can be overcome by increasing the dose of vector and by suppressing immune responses.
Introduction
The beta cells of the pancreas produce insulin, which in turn
induces upregulation of the glucose transporter GLUT4 in
many cell types, allowing efficient glucose uptake. When the
beta cells are destroyed or incapacitated, as happens in type 1
diabetes, insulin is no longer produced in sufficient amounts
and the tissues are unable to metabolise glucose despite it
being abundant in the circulation. This disease was deadly
until the 1920s when the insulin protein was identified [1],
and administration of exogenous insulin has remained the
available therapy for the disease since this discovery.
The success of gene therapy introducing hepatic expression
of clotting factors in people with haemophilia B [2–4], and
more recently expanding to other disorders [5, 6], demon-
strates that this approach is feasible in human patients. The
possibility of producing insulin endogenously via gene therapy
is appealing as a form of basal long-acting insulin. We have
demonstrated that the vector used for haemophilia therapy can
be successfully modified to express insulin, and can restore





1 Department of Pathology, University of Cambridge, Tennis Court
Road, Cambridge CB2 1QP, UK
2 Department of Surgery, National University of Singapore,
Singapore, Singapore
3 Institute of Metabolic Science, Addenbrooke’s Hospital,
Cambridge, UK
4 Dick White Referrals, Station Farm, Six Mile Bottom, Suffolk, UK
5 Department of Haematology, UCL Cancer Institute, London, UK
6 Department of Medicine, University of Cambridge, Cambridge, UK
7 Department of Medicine, National University of Singapore,
Singapore, Singapore
8 Department of Surgery, University of Cambridge, Cambridge, UK
Supplementary material The online version of this article (https://
doi.org/10.1038/s41434-018-0052-5) contains supplementary















diabetic mice [7]. Other groups have previously achieved
restoration of insulin production through gene therapy using
either naked DNA [8, 9] or various viral vectors [10–16] in
animal models, as reviewed in [17]. These studies show that
the insulin gene can be expressed in vivo after gene therapy,
and can restore euglycaemia in diabetic hosts that have been
rendered diabetic by chemical ablation of the beta cell popu-
lation. However, type 1 diabetes is very different from hae-
mophilia, and even if insulin can be expressed successfully
there are additional challenges that need to be overcome before
insulin gene therapy could be considered in people with type 1
diabetes. One of those challenges is the autoimmune aetiology
of the disease, with autoreactive T cells reported as the cause
of beta cell destruction (reviewed in [18]). The recurrence of
autoimmunity, resulting in the destruction of the de novo
insulin expressing tissue, is an obvious concern.
We were interested in whether hepatic expression of
insulin mediated via the previously described AAV2/8-based
vector [7] could restore euglycaemia even in a completely
immunocompetent host, particularly where there is already
pre-existing autoimmunity to the insulin protein. In people
with haemophilia, the occurrence of T cells reactive against
the transgenic blood clotting factor IX coincided with
reduced expression of the transgene, and treatment with
glucocorticoids was required to stabilise the transgene
expression [2]. As insulin-producing beta cells are a major
target for the autoimmune response responsible for destroy-
ing the beta cells in the first place [19, 20], it is not unrea-
sonable to expect that even if transgenic insulin can be
expressed, the autoreactive T cells and B cells may become
reactivated to destroy the successfully transfected cells. Stu-
dies of pancreas transplantation have demonstrated that even
when a diabetic islet graft recipient received a completely
human leucocyte antigen-matched graft from an identical
twin, reactivation of anti-islet immune responses led to rapid
destruction of the graft [21]. In diabetic NOD mice, syn-
geneic islet grafts are destroyed within 10 days unless potent
immunosuppression is administered [22, 23]. Immune
responses to the vector itself can also limit the efficacy of the
treatment [24]. Thus, we were concerned that long-term
restoration of insulin production in mice with autoimmune
diabetes would be compromised by recurring immune
responses destroying the insulin-producing hepatocytes.
Results
Spontaneously diabetic NOD mice require higher
doses of AAV2/8-HLP-hINSco-mediated gene
therapy to restore euglycaemia
Male C57BL/6 mice were injected with streptozotocin to
destroy the beta cells, and female NOD mice were
monitored for diabetes and selected for treatment once
consecutive tests proved them to be irreversibly diabetic.
They were then injected with AAV2/8-HLP-hINSco at a
dose of 5 × 109 viral genomes (vg)/mouse, which had pre-
viously proven successful in immunocompromised mice
[7], and which we confirmed in our colony of NODscid mice
(S1). This dose completely restored euglycaemia in diabetic
C57BL/6 mice (Fig. 1a), indicating that the presence of a
fully functional immune system did not affect transduction
and expression of the transgene. However, the same dose
had no effect on glycaemia in spontaneously diabetic NOD
mice (Fig. 1b), although the treated mice maintained stable
body weight (S2). When tested for transgenic human C-
peptide, a cleaved product of proinsulin which is used as
read-out of insulin production, diabetic NOD mice had
lower levels in serum after treatment (Fig. 1b, bottom panel)
than C57BL/6 (Fig. 1a, bottom panel), indicating less
effective transduction of the vector (or survival of the
transduced cells). This result was further supported by the
lower average of genome copy number of virus per liver
cell (Fig. 1c) and the lower expression of human insulin
mRNA in the liver (Fig. 1d) in NOD mice. When the dose
was increased five-fold, to 25 × 109 (Fig. 2a), we observed a
lowering of blood glucose in the naturally diabetic female
NOD mice. An additional increase to 35 × 109 vg did not
allow complete control of hyperglycaemia either (data not
included). Only when the dose was further increased to
40 × 109 vg the diabetic NOD mice were restored to normal
blood glucose levels (Fig. 2a). A dose of 50 × 109 was also
administered, but the mice had to be culled due to sustained
severe hypoglycaemia (data not included). Even though the
lower dose of 25 × 109 did not restore normoglycaemia in
the diabetic mice, the insulin produced was enough to
maintain a normal body weight gain (Fig. 2b). Increasing
the dose correlated with increased levels of transgenic
human C-peptide in the serum of the treated mice (Fig. 2c,
d) and increased expression of transgenic human insulin
mRNA in the liver (Fig. 2e).
The transgenic insulin is secreted continuously and is not
regulated by blood glucose levels and incretin hormones.
This can cause hypoglycaemia unless sufficient amounts of
glucose are ingested, which we observed when titrating the
vector dose in diabetic NOD mice. We therefore investi-
gated whether withdrawal of food would cause hypogly-
caemia episodes in the mice receiving tolerated doses of
AAV2/8-HLP-hINSco. We observed a lowering of blood
glucose levels in all NOD mice, including the untreated
diabetic ones, after overnight fasting, but none dipped to
levels below 3.3 mM (S3).
The difference in effect was not due to the sex difference
[25] between the female NOD mice and the male C57BL/6,
as chemically induced diabetic male NOD mice also resis-
ted restoration of euglycaemia with 5 × 109 vg/mouse
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(S4A), and had human C-peptide levels similar to the
spontaneously diabetic female NOD mice treated with the
same dose (S4B). Male NOD mice have activation of islet-
specific immune responses and develop inflammatory
infiltrates in the pancreatic islets just like the female mice,
but progress to diabetes less frequently. This necessitates
the use of streptozotocin or other drugs to precipitate dis-
ease in the males, but the mice also have the underlying
anti-islet immune reactivity and fully functional NOD
mouse immune system.
Diabetic NOD mice treated with 25 × 109 vg achieved
similar levels of serum human C-peptide as the C57BL/6
mice treated with 5 × 109 vg (a five-fold increase of the
dose) (Fig. 2c vs Fig. 1a). An even higher dose was
necessary to achieve adequate glucose control (Fig. 2a). If
diabetic NOD were insulin resistant, this could explain the
requirement for more insulin to restore euglycaemia. An
insulin tolerance test was therefore performed, where the
rapidity and magnitude of the blood glucose-lowering effect
of a bolus injection of insulin was recorded (S5A). This
Fig. 1 Administration of 5 × 109 vg/mouse AAV2/8-HLP-hINSco
restores normoglycaemia in chemically induced diabetic C57BL/6
mice but not in naturally diabetic NOD mice. C57BL/6 male mice (a),
rendered diabetic with streptozotocin (40 mg/kg i.p. for 5 days), or
NOD female mice (b), tested positive for diabetes more than three
consecutive times, were treated with AAV2/8-insulin therapy (indi-
cated as AAV2/8) (day 0). Blood glucose levels were then monitored
over time (a, b top panels). Plasma human C-peptide levels of C57BL/
6 (a, bottom panel) and NOD (b, bottom panel) mice were measured
over time after AAV2/8-HLP-hINSco injection. c Average genome
copy number of virus per liver cell at the end of the 30-day experi-
ments. d Transgenic human insulin mRNA expression in the treated
C57BL/6 and NOD mice livers relative to C57BL/6 mice’s levels at
the end of the 30-day experiments. Data shown are expressed as mean
± SE and are representative of two independent experiments
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demonstrated no difference in the response in NOD mice
(S5B) and C57BL/6 (S5C). If anything, the diabetic
C57BL/6 mice showed a less striking response to insulin
challenge than the diabetic NOD mice. In addition, healthy
NOD mice and C57BL/6 mice secreted comparable
amounts of insulin in response to glucose challenge (S5D),
indicating that NOD mice do not normally require more
insulin to control blood glucose.
Transgenic insulin in AAV2/8-HLP-hINSco-
transfected liver cells reactivates cellular immune
responses in NOD mice
Both insulin (Fig. 3a, b) and C-peptide (Fig. 3b) can be
detected in the livers of treated C57BL/6 mice (Fig. 3b, top)
and NOD mice (Fig. 3b, middle and bottom panels), but not
in untreated controls (Fig. 3a, left). Closer examination
Fig. 2 Increased dose of the vector allows to better control blood
glucose levels in diabetic NOD mice. a Established diabetic NOD
females were injected with either 25 × 109 vg/mouse (a, light blue) or
40 × 109 vg/mouse (a, dark blue) AAV2/8-HLP-hINSco vector (indi-
cated as AAV2/8), or vehicle only (a, red line) (day 0) and were then
monitored for blood glucose levels. b Percentage of weight change
from baseline for the mouse groups in a. c, d Plasma human C-peptide
levels measured over time after AAV2/8-HLP-hINSco injection. e
Transgenic human insulin mRNA expression in the livers of NOD and
C57BL/6 mice transduced with different doses of AAV2/8-HLP-
hINSco as indicated in the figure. Expression is relative to C57BL/6
levels and was determined after more than 200 days from infection.
Data shown are expressed as mean ± SE and are representative of two
independent experiments
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reveals colocalization of insulin and C-peptide staining on a
cellular level (Fig. 3c). However, the initial destruction of
the pancreatic beta cells in the NOD mice is immune
mediated (Fig. 4a, top panels), while the chemically induced
diabetic C57BL/6 mice lack immune infiltration around the
sparse insulin-positive cells that remain after treatment
(Fig. 4a, middle panels). Analysis of total endogenous
insulin mRNA corroborates the conclusion that although
some beta cells are present in the pancreata of the diabetic
streptozotocin-treated C57BL/6 mice, these are very rare
(S6). Overtly diabetic AAV2/8-HLP-hINSco -treated NOD
mice have no endogenous beta cells left in their pancreata
while glucagon-positive alpha cells remain, and a few
infiltrating T cells can still be seen in the surrounding tissue
(Fig. 4a, bottom panels). Importantly, T cells can also be
detected in the livers of diabetic AAV2/8-HLP-hINSco-
treated NOD mice (Fig. 4b, right) (5.2 ± 1.24 per liver
section n= 5), but not in the treated C57BL/6 mice (Fig. 4b,
left). These T cells consist mainly of CD8+ T cells (Fig. 4c)
(3.6 ± 0.51 per liver section n= 5). The reactivation of
insulin-specific T cells was detected with IFN-γ ELISPOT
revealing that there were significantly more IFN-γ-
producing CD8+ T cells in diabetic AAV2/8-HLP-hIN-
Sco-treated NOD mice than in untreated NOD mice both at
30 days (Fig. 4d, bottom panels) and 200 days (Fig. 4e,
bottom panels), while the CD8+ T cells from C57BL/6 mice
produced negligible levels of IFN-γ in response to insulin
peptide both before and after treatment at all time points
(Fig. 4d, e, top panels). Cells from both mouse strains
responded well to polyclonal activation with PMA and
Ionomycin (S7). Interestingly, NOD mice not only
demonstrated a more vigorous response to insulin, but also
to peptide from the AAV2/8 vector itself (Fig. 4e, bottom
right panel), indicating that NOD mice have more easily
triggered immune responses in general. This hypothesis is
further supported by the fact that splenocytes from treated
NOD mice produced significantly less of the immunosup-
pressive cytokine interleukin-10 (Fig. 4f) but more of the
anti-AAV8 antibodies (Fig. 4g) than those from treated
C57BL/6, and displayed an overall higher metabolic
activity (S8).
Diabetic NOD mouse recipients of AAV2/8-HLP-
hINSco required higher doses of vector, and had higher
levels of serum human C-peptide on achieving eugly-
caemia than C57BL/6 mice (Figs. 1 and 2). Even when
mostly restored, previously diabetic NOD mice displayed
more fluctuating blood glucose readings, indicating a
less stable supply of insulin (Fig. 2a). We wondered if the
anti-insulin antibodies present in the serum of NOD mice
(S9) could bind the transgenically produced human
insulin, and thus contribute to a situation where the insulin
is present but inactive. This phenomenon has been
described in insulin-treatment naïve people presenting
with hypoglycaemic episodes (described as insulin auto-
immune syndrome (IAS) or Hirata disease [26]) as well as
in patients with labile diabetes treated with modern
genetically engineered insulin analogues. Insulin bound
by antibodies can lose its biological effect and its half-life
increases from 4 to 6 min to several weeks. We used a
mass spectrometry based peptidomics analysis of serum
after acetonitrile precipitation [27], which allows release
of any bound insulin from antibodies, to assess whether
the treated NOD mice had more transgenic human insulin
in their serum. The peptidomics approach identified pep-
tides derived from the human insulin transgene
circulating in the plasma of AAV2/8-HLP-hINSco-treated
mice, in particular the C-peptide (S10A), which showed
the highest signal. These transgene derived peptides were
only detected in the AAV2/8-HLP-hINSco-treated mice.
We could detect peptides derived from both the A- and B-
chain of human insulin in both mouse strains, with
no significantly higher abundance in NOD mice, sug-
gesting no antibody-mediated serum insulin concentration
increases were in effect (S10B).
Fig. 3 Transgenic insulin is stored in intracellular granules of AAV2/
8-insulin-transduced liver cells. Healthy control (a, left) and AAV2/8-
HLP-hINSco-treated (indicated as AAV2/8) (a, right) NOD mouse
liver sections stained for insulin. Co-localisation of insulin (red) and
C-peptide (green) in liver sections of C57BL/6 mice (b, top panel) and
NOD female mice (b, middle panel) injected with 5 × 109 vg AAV2/8-
HLP-hINSco after 30 days, and NOD female mice injected with 40 ×
109 vg after 218 days (b, bottom panel). Scale bar 50 μm. Magnifi-
cation of a transduced liver cell in c, where scale bar is 5 μm. Blue
shows nuclear staining. Images are representative of at least two
experiments
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Suppression of adaptive immune responses
improves the effect of AAV2/8-HLP-hINSco in
naturally diabetic NOD mice
Injection of non-depleting anti-CD4 antibody YTS177
can suppress adaptive immune responses and induce
immunological tolerance to islet antigens and AAV capsid
[28], but if administered alone cannot reverse overt
spontaneous diabetes in NOD mice [29–31]. To determine
whether suppression of adaptive immune responses could
increase the efficacy of the vector, we investigated whe-
ther co-treatment with YTS177 affected restoration of
euglycaemia (Fig. 5a). Fifty percent of the diabetic NOD
mice injected with low dose (25 × 109 vg/mouse) AAV2/
8-HLP-hINSco, and also treated with repeated injections
of YTS177, achieved reversal of diabetes (here defined as
blood glucose levels decreasing to below 13 mM), while
none of the mice treated with isotype control antibody,
vector alone or anti-CD4 antibody alone did (Fig. 5b). The
CD4 blockade clearly decreased adaptive responses, as
the production of anti-AAV8 antibodies was significantly
decreased in YTS177-treated mice (Fig. 5c) and human C-
peptide levels increased in those mice responding to the
combination therapy (Fig. 5d, red arrows).
Fig. 4 AAV2/8-insulin-based therapy elicits a cellular immune
response against the vector and the transgene in NOD diabetic mice.
Livers of NOD mice treated with AAV2/8-HLP-hINSco (indicated
with AAV2/8) show signs of T cell infiltration observed in pre-diabetic
NOD mouse pancreata. a Pancreas sections from a 8-week-old control
NOD female pancreas (a, top panel), a 30-day AAV2/8-insulin-treated
C57BL/6 (a, middle panel) and a 30-day AAV2/8-insulin-treated NOD
(a, bottom panel) were stained for insulin (red) and glucagon (green),
and CD3 (yellow) to show β-cell destruction in treated mice. b Livers
from AAV2/8-HLP-hINSco -injected C57BL/6 (b, left) and NOD (b,
right) mice were stained for insulin and CD3 to test for T cell infil-
tration. c Livers from AAV2/8-HLP-hINSco-injected NOD mice were
stained for insulin and CD8. Blue shows nuclear DAPI staining. Scale
bar 50 μm. d, e Ex vivo stimulated splenocytes from AAV2/8-HLP-
hINSco -treated NOD mice and C57BL/6 controls for IFN-γ ELISPOT
assay. Cells from NOD and C57BL/6 mice were harvested after
30 days (d) or more than 200 days (e) from the day of the injection of
the AAV2/8-insulin vector. Cells were stimulated in vitro for 40 h with
CD8+ immunodominant peptides (either InsB15–23 peptide for NOD or
insulin Kb-restricted epitope A12–21 containing peptide for C57BL/6) or
the AAV8 capsid-specific CD8+ T cell peptide NSLANPGIA and the
number of resulting IFN-γ spots was counted with an ELISPOT
reader. f Levels of anti-inflammatory cytokines in NOD mice com-
pared to C57BL/6. Splenocytes from C57BL/6 and NOD mice were
harvested at the end of a 30-day treatment with AAV2/8-HLP-hINSco
5 × 109 vg and stimulated with PMA/Iono for 48 h. Supernatants were
then collected and tested for IL-10 production. g Mouse anti-AAV8
ELISA performed on blood plasma of diabetic, healthy and 5 × 109 vg
AAV2/8-HLP-hINSco-treated NOD and C57BL/6 mice. Treated mice
were tested for anti-AAV8 antibodies 30 days after the beginning of
the therapy. The absorbances at 405 nm correlate with the concentra-
tion of the antibody. *(p ≤ 0.05), **(p ≤ 0.01), ***(p ≤ 0.001), unpaired
Student’s t-test. Data shown are expressed as mean ± SE and are
representative of two independent experiments
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Efficacy of AAV2/8-HLP-hINSco in NOD mice is
inhibited by vector specific immunity
The anti-CD4 treatment showed that adaptive immune
responses could prevent the efficacy of the vector, but it did
not specify whether the inhibiting immune responses were
specific for insulin in particular. To elucidate this, we used a
different vector, which expressed luciferase rather than
insulin, allowing the transduction efficacy to be imaged
in vivo at different time points after injection using whole-
body imaging. If the inhibition seen in diabetic mice had
been insulin-specific, the efficacy of this luciferase-
containing vector should have been equally high in NOD
mice (Fig. 6a), C57BL/6 mice (Fig. 6b), and NODscid mice
(Fig. 6c). However, even with this vector we observed
much lower expression in the immunocompetent healthy
Fig. 5 Dampening the immune response improves therapeutic efficacy
of gene therapy in naturally diabetic mice. a Established diabetic NOD
mice were treated with either the IgG2a isotype control (MAC219), or
a non-depleting antibody to CD4 (YTS177), or a combination of anti-
CD4 and 25 × 109 vg/mouse AAV2/8-HLP-hINSco (indicated as
AAV2/8). b Blood glucose measurements for each experimental
mouse were taken from the day of AAV2/8-insulin vector injection
and are represented as average in a survival curve showing the
percentage of diabetic mice. *(p ≤ 0.05), log-rank survival test. c Blood
plasma of experimental mice tested for anti-AAV8 antibodies by
ELISA. The absorbances at 405 nm correlate with the concentration of
the antibody. *(p ≤ 0.05), unpaired Student’s t-test. d Human C-
peptide levels of individual experimental mice (numbered 1–6) at day
10, 30 and 60 from the day of AAV2/8-HLP-hINSco injection. Arrows
indicate mice responding to the CD4 blockade/AAV2/8-insulin com-
bination therapy. Data shown are expressed as mean ± SE
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NOD mice than healthy C57BL/6 mice (Fig. 6a, sum-
marised in Fig. 6d), indicating that although insulin-specific
responses are reactivated in the vector-treated NOD mice,
with accompanying T cell infiltration into the liver, the
blocking immune responses also have other targets.
To further test whether antibody responses to AAV
vector or insulin could block effective transduction with the
vector, we performed an antibody transfer experiment. We
rendered NODscid male mice diabetic with streptozotocin,
and then treated them with 5 × 109 vg/mouse, the dose that
had previously demonstrated complete restoration of
euglycaemia in immunodeficient NSG mice [7] and
NODscid mice (S1). NODscid mice have a complete lack of
an adaptive immune system and very limited generation of
antibodies [32]. We performed serum transfer every day
from day 4 (the earliest time point in immunocompetent
NOD mice when AAV8-specific antibodies can be detected
after infection) to day 10 after AAV2/8-HLP-hINSco
treatment, with either AAV2/8-HLP-hINSco-exposed
serum or control NOD serum (Fig. 7a). We found that the
5 × 109 vg/mouse dose restored euglycaemia in diabetic
NODscid male mice just as we had observed previously. In
addition, we found that serum from AAV2/8-HLP-hINSco-
exposed NOD mice blocked restoration of euglycaemia in
the diabetic NODscid males, while control NOD mouse
serum did not (Fig. 7b, left and right panels). The AAV2/8
vector exposed serum was harvested from exposed NOD
mice 9 days after injection, a time point when a strong
antibody response has been established. The transferred
antibodies were also able to block transduction of cells with
vector coding for GFP in vitro (Fig. 7c).
Discussion
We investigated whether an AAV2/8 vector expressing
furin cleavable insulin under the liver-specific promoter
(HLP), which can restore euglycaemia in streptozotocin-
induced diabetic immunocompromised mice [7], is also
effective in immunocompetent streptozotocin-induced
Fig. 6 Low transduction levels
in NOD mice infected with
AAV2/8-insulin therapy are not
specific to the insulin transgene.
NOD (a), C57BL/6 (b) and
NODscid (c) mice were injected
i.v. with different doses of
ssAAV2/8-HLP-Luciferase
(indicated as AAV2/8). After
10 days, mice were injected i.p.
with luciferin, anaesthetized and
measured for live luminosity by
an image capturing device
(IVIS). Quantification of
luminescent intensity (photons/
second) for the boxed areas in
a–c with background signal
deducted (d)
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diabetic mice, and in spontaneously diabetic non obese
diabetic (NOD) mice. We also investigated the occurrence
of immune responses to the vector and the transgene in each
of these conditions. We find that AAV2/8-insulin gene
therapy can indeed correct hyperglycaemia in both of these
models of diabetes, but that the dose requirements for
success in autoimmune, spontaneously diabetic NOD mice
is 7–10-fold higher than in non-autoimmune C57BL/6
mice. This is not due either to increased insulin resistance in
the NOD mice, or to differences between male and female
mice. Diabetic NOD mice have established T cell responses
to insulin, and these are reactivated by the introduction of
insulin expression in the liver cells. The epitope studied,
InsB15-23 (LYLVCGERG), is conserved between mouse-
and human insulin [33]. We see evidence of immune
infiltration in the livers of vector-treated NOD mice,
accompanied by increased activation of insulin-specific
CTL; however, the mice treated with the higher doses of
vector retain high and stable levels of human C-peptide in
the serum. We hypothesised that anti-insulin antibodies may
Fig. 7 Anti-AAV2/8 passive immunisation diminishes the AAV2/8-
insulin-mediated therapeutic effect in diabetic NODscid mice. a
NODscid male mice rendered diabetic with streptozotocin (40 mg/kg i.
p. for 5 days) were treated with 5 × 109 vg AAV2/8-HLP-hINSco
(indicated as AAV2/8) (day 0). The serum of immunocompetent NOD
mice either injected with 5 × 109 vg or vehicle only was injected i.p.
into the NODscid mice 4 days after the beginning of the therapy and for
the following 7 days. The start date of passive immunisation was
temporally determined by the appearance of anti-AAV8 antibody
response in the immunocompetent NOD mice via ELISA. Blood
glucose levels of treated animals monitored over time represented both
as average measurements ± SE (b, left) and as a resulting percentage of
diabetic mice (b, right). Statistical difference measured against diabetic
control. Ns = non significant, *(p ≤ 0.05), log rank survival test. c
NOD serum used to passively immunise AAV2/8-insulin-treated
NODscid has AAV2/8 blocking capabilities conferred by anti-AAV2/8-
neutralising antibodies. Percentage of cell transduction in an in vitro
viral neutralising assay. Number of transduced cells was normalised to
positive control. AAV2/8 haemophilic represents a serum sample
coming from an AAV2/8-treated dog known to have developed
immunity against the vector. Statistical difference compared to posi-
tive control, *(p ≤ 0.05), **(p ≤ 0.01), two-way Anova
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contribute to a need for higher insulin secretion by neu-
tralising the released insulin product, a condition known as
Hirata’s syndrome. We utilised a novel mass spec-based
technique to assess the presence of antibody–insulin com-
plexes in the serum of AAV2/8-HLP-hINSco-treated NOD
mice, but found no evidence of this. However, anti-
inflammatory treatment with non-depleting CD4+ T cell
antibody increased the efficacy of the AAV2/8-insulin gene
therapy treatment, allowing restoration of euglycaemia
using a lower dose that was not effective in isotype
antibody-treated diabetic control NOD mice. Furthermore,
transfer of AAV2/8-HLP-hINSco-reactive serum from pre-
viously treated NOD mice also decreased the efficacy of the
treatment in NODscid mice, indicating that both T cell and B
cell mediated responses act as barriers to AAV2/8-insulin
gene therapy success.
Our data indicate that there are barriers to effective
AAV2/8-insulin gene therapy in autoimmune NOD mouse
recipients, and that these are caused both by reactivation of
anti-insulin immune responses as well as a generalised
higher activation state of the NOD mouse immune system.
We saw reactivation of anti-insulin-specific CD8+ T cells,
and infiltration of T cells in the liver where the insulin
transgene is expressed, but although these responses almost
certainly contribute to the prevention of effective AAV2/8-
insulin therapy, it is also clear that vector-specific immune
responses play a major role in NOD mouse resistance. In
order to counteract the immune mediated destruction of
insulin or insulin-producing cells, it is plausible that higher
circulating levels of transgene are required to allow stable
supply of insulin and therefore proper glycaemic control.
NOD mice have a deficiency in the inhibitory Fc receptor
FcγRIIb, leading to greater production of antibody after
stimulation [34, 35]. We show that the autoimmune NOD
mice generate higher titres of anti-AAV antibodies, and our
serum transfer experiments demonstrate that these anti-
AAV antibodies can block efficacy of the treatment.
However, immunosuppression with cyclosporine [28] or
non-depleting anti-CD4 antibody [28] (and data presented
in this report) can inhibit the priming or reactivation of
immune responses.
A strong antibody response to the AAV2/8 vector was
observed in immunocompetent mice only after 9 days from
the day of gene therapy administration. At that point it is
plausible to infer that the transduction of most targeted cells
had already occurred as well as the expression of transgenic
insulin. In the absence of cellular immune response towards
the vector or the transgene, therapeutic efficiency could be
long-lasting and negatively impacted only by the turnover
rates of transduced cells. It is still not clear how long AAV
particles can be detected in vivo and the effect that this
could have on cellular immunity in the long term. However,
our data seem to suggest that in NOD mice AAV2/8 capsids
gain access to the MHC class I antigen presentation path-
way and trigger capsid-specific CD8+ T cell responses.
This, in combination with the enhanced transgene immu-
nogenicity and possibly robust innate immune recognition
of AAV, could induce the destruction of transduced hepa-
tocytes. This phenomenon was observed only in the livers
of the treated NODs, not in the C57BL/6 mice. The
enhanced immunogenicity of vector and transgene in the
NOD mice could be promoted by an environment less
immunologically tolerant, a result also of the different
microbiome composition [36, 37]. The therapeutic high
dose of vector used for the NOD mice could also exacerbate
the deleterious immune response already seen with lower
doses.
An important observation is the very high efficacy of the
AAV2/8-mediated insulin gene therapy treatment in
NODscid mice, which are immunodeficient due to a deletion
in the DNA repair gene Prkdc that prevents successful
recombination of T- and B cell receptors [32]. The gene
product from this gene, DNA-PK, which is also a compo-
nent of the system that senses foreign nucleotides in the cell
to initiate innate immune responses [38] has been reported
to be important for successful infection with AAV viruses
[39], raising the possibility that the big difference in dose
requirement between diabetic NOD mice and diabetic
NODscid mice may be due to the effects of this gene on
innate immunity in addition to effects on adaptive
immunity.
The liver itself has tolerogenic properties, due to a
microenvironment characterised by low over all MHC class
I expression and an abundance of particular antigen-
presenting cells [40]. Transplant recipients who receive a
combined kidney and liver transplant have lower rejection
rates and sustain better glomerular filtration 5 years after
transplant than recipients of kidney transplant alone [41].
This may in part be caused by tolerogenic properties of
antigen presentation within the liver, particularly by the
liver-resident Kupffer cells [42] which can expand the
population of regulatory T cells [43]. Previous studies have
shown that AAV-mediated expression in the liver can
facilitate immune tolerance to clotting factors in mice [44],
and, perhaps of greater importance to our present study,
lentiviral vector-mediated liver-specific expression of the
immunogenic insulin peptide InsB15-23 can induce insulin-
specific Treg-mediated immune tolerance in NOD mice
[45]. It is possible that the sporadic nature of the immune
infiltration in the livers and the longevity of transgenic
insulin expression in AAV2/8-insulin-treated NOD mice, in
spite of the recorded reactivation of effector immune cells,
reflects a similar induction of immune tolerance.
Secretion of sequestered insulin from beta cells is regu-
lated by levels of surrounding glucose and signals induced
by incretins from the gut. If too much insulin were secreted
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with insufficient glucose around there is a risk of hypo-
glycaemia, as we found when titrating the vector dose,
which can be lethal. This is a serious concern when con-
sidering clinical application of insulin gene therapy. Several
approaches have been suggested to solve this, for example,
use of glucokinase to increase uptake [13], controlled
sequestration in the ER [46] and the use of S14-based
glucose-inducible regulatory elements [16], but it remains
difficult to imagine a gene therapy approach that could fully
imitate the efficient and sensitive responses and release
mechanisms of the natural beta cell. In fact, it may be
detrimental to devise a glucose responsive system which
reacts to glucose levels several hours in the past, as a
promoter-based system would. An alternative approach is to
support the existing beta cell population rather than replace
it by targeting insulin-like growth factor 1 (IGF1) expres-
sion to the beta cells using gene therapy. This approach has
yielded positive results in NOD mice [47]. Regardless of
which system is ultimately chosen, identifying the immu-
nological barriers to treatment and strategies to overcome
them will be of central importance for achieving success.
For most monogenic disorders, the approach commonly
adopted to reduce or avoid AAV-capsid-specific humoral
and cellular responses upon gene therapy treatment, is the
administration of immune-suppressive drugs. As shown by
McIntosh et al. [28] and Han et al. [48], transient immu-
nosuppression achieved at the time of vector administration
allows successful attenuation of antibody response to the
vector and the transgene, with increased transduction effi-
ciency, in models of haemophilia B and Pompe diseases.
Importantly, this strategy allows also for vector read-
ministration, which is particularly relevant for chronic dis-
orders where the therapeutic effect of one round of infection
may not be life long due to changed protein level require-
ments and/or turnover rates of the transduced cells. In our
study we showed that the combination of an immunomo-
dulatory agent such as the non-depleting anti-CD4 antibody
with AAV-based insulin gene therapy allowed increased
therapeutic benefit also for Type 1 diabetes. This could be
the way forward also for human autoimmune diabetes,
should the AAV-based treatment be taken to the clinic. As
general immunosuppression protocols are associated with
considerable side effects, such as increased susceptibility to
infection [49] as well as reactivation of dormant infections
[50], it is important to weigh up the risk–benefit ratio for
any given approach. Further pre-clinical investigations
could help to identify safe and specific transient capsid-
derived antigen immunomodulators that would circumvent
the risks associated with systemic immunosuppression.
These pharmaceutical agents would ideally still allow for
induction of robust long-term peripheral tolerance to the
transgenic insulin and would not affect transduction
efficiency.
In conclusion, AAV2/8-mediated liver-specific insulin
gene therapy is inhibited by both insulin- and vector-
specific immune responses in autoimmune diabetic NOD
mice, but efficacy and long-lasting expression of transgenic
insulin can be achieved by increasing the dose of vector and
by administering immunosuppressive treatment. Despite
raising a modest anti-AAV2/8 antibody response, immu-
nocompetent C57BL/6 mice respond well to the treatment.
This, in agreement with a previous study of immuno-
competent CD-1 mice rendered diabetic with streptozotocin
[15], indicates that the presence of a functional immune
system does not represent an impediment to the success of
the AAV-mediated gene therapy per se, but that particular
qualities of the recipient immune response dictate the out-
come. This could be important when considering clinical
application. Furthermore, low-dose-treated diabetic NOD
mice, which failed to return to normoglycaemia, continue to
gain weight and appear well, suggesting that even low doses
of insulin gene therapy vector can have beneficial effects
while avoiding the risk of causing hypoglycaemia. Our data
suggest that low expression of transgenic insulin could
function as a complement to insulin injections, and has the
potential to improve quality of life in people with diabetes.
Methods
Mice
NOD and NODscid mice were bred at the Department of
Pathology, University of Cambridge. C57BL/6 male mice
were purchased from Envigo and entered experimental
protocols between 6 and 10 weeks of age. The mice were
housed in individually ventilated cages and kept under
controlled light (12 h light/dark cycles), temperature, and
humidity conditions. They had free access to water and
food, unless otherwise stated. This study was carried out in
accordance with UK Home Office regulations and approved
by the University of Cambridge Animal Welfare and Ethical
Review Body.
Chemical induction and confirmation of diabetes
NOD, NODscid and C57BL/6 male mice were injected
intraperitoneally for five consecutive days with Streptozo-
tocin (STZ, Sigma-Aldrich, 40 μg/g body weight) dissolved
in citrate buffer (pH 4.2). No loss of mice occurred as a
result of the STZ treatment. Diabetes normally developed
within 10–14 days [51]. Eighty per cent of NOD female
mice naturally developed diabetes between 12 and 30 weeks
of age.
Body weight was measured and blood glucose tested
via the tail vein with a glucometer. Mice were considered
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diabetic when blood glucose levels were >13.5mM on three
successive days as determined by a Contour Next blood
glucose monitoring System (Bayer). Established diabetic mice
were randomly divided into different groups of similar sizes,
mixed between different cages. Power calculation to deter-
mine group sizes were performed using the www.dssresearch.
com online resource. The investigators were not blinded to the
group allocation or analysis; however, the readout consisted
of objective blood glucose measurements not affected by the
operators’ expectations. Any treated or control mice
approaching loss of 15% of original body weight or otherwise
showing signs of reduced wellbeing were culled in accor-
dance with Home Office regulations. Long-lasting monitoring
of treated mice was performed for as long as allowed by the
Home Office project licence under which this work was
carried out.
Gene therapy treatment
ssAAV2/8-HLP-hINSco vector (co stands for codon
optimised) encoding the furin cleavable human proinsulin
gene [52] was designed, assembled, purified and
titrated as previously described [7]. The production of the
vector was either performed at UCL or commissioned
from the Penn Vector Core Facility (University of Penn-
sylvania). Confirmed diabetic mice were injected intra-
venously with either the indicated doses of AAV2/8-HLP-
hINSco or an equivalent volume of saline solution as per
controls. Body weights and blood glucose levels were
monitored on a daily basis from the beginning of the
therapy. Blood, sampled from the lateral tail vein at
the indicated time points, was collected in lithium-heparin
tubes (VWR International) for plasma separation and then
analysed for human C-peptide production on a
Diasorin Liaison XL automated immunoassay analyser
using a one-step chemiluminescence immunoassay (Kit
No. 316171) in the Cambridge Biochemical Assay
Laboratory, Addenbrooke’s Hospital. All reagents, stan-
dards and consumables are those supplied by the
manufacturer.
Assessment of impaired glucose metabolism
Treated and control animals were subjected to fasting by
withdrawing the food from the cages for 16 h while still
providing access to water.
To determine the sensitivity of insulin receptors,
experimental mice were subjected to insulin tolerance tests.
Mice were fasted for 6 h with access to water and were then
injected intraperitoneally with 0.375 μU human insulin
(Lilly)/g body weight and tested for blood glucose at 0, 15,
30, 60 and 120 min after injection. Results were then nor-
malised to baseline fasting glucose.
To assess insulin production in response to glucose
challenge, the mice were fasted overnight, then glucose (1
mg/g of body weight, in PBS) or vehicle alone was injected
s.c. in the scruff of the neck. Blood was drawn after 15 min,
and serum prepared and analysed for mouse insulin using
the Mesoscale assay (MSD) at the Cambridge Biochemical
Assay Laboratory, University of Cambridge.
In vitro AAV neutralisation assay
293T cells were obtained from the American Type Culture
Collection (ATCC, VA, USA) maintained in Dulbecco's
modified Eagle's medium (DMEM) (Sigma) supplemented
with 10% foetal calf serum (FCS), 1% glutamine and 1%
penicillin/streptomycin at 37 °C and 5% CO2. 2 × 10
4 cells/well
in complete medium were seeded into 96-well plates the
morning of infection. The mouse sera to test were heat-
inactivated at 56 °C for 1 h and diluted in DMEM with con-
centrations ranging from 1/4 to 1/5000. Wells with the same
volume of diluted FCS served as controls. 2 × 108/well viral
genomes of scAAV2/8-CMV-GFP vector diluted in an equal
volume of DMEM were added to the diluted mouse sera and to
some of the diluted FCS sera (positive controls), incubated at
37 °C for 30min and then added to the 293T cells 5 h after cell
plating. Negative controls did not receive any virus. In order to
evaluate levels of inhibition, a serum sample obtained from a
haemophilic dog 65 days after AAV8-based therapy injection
was used for the assay. Thirty-six hours after infection, the
transduction efficiency was analysed by quantifying the num-
ber of GFP+ 293T cells via flow cytometry (FACSCalibur,
BD, New Jersey, USA). The percentage of inhibition was
calculated relative to positive FCS control samples.
Immunoassays
Plasma samples from mice were tested for the presence of
antibody against human insulin and AAV8 using an ELISA.
Ninety-six-well plates were coated overnight with either
scAAV2/8-CMV-GFP (5 × 108 vg/well) or Human insulin
solution (Sigma, 10 μg/ml) diluted in 0.1 M NaHCO3 (pH
9.2), or NaHCO3 only. Wells were washed with 0.05%
PBST (PBS with Tween 20) and blocked with 6% bovine
serum albumin (BSA)/PBST for 1 h at 37 °C. Plasma
samples diluted 1/1000 in 2% BSA/PBST (or dilution
buffer only as for assay control) were applied to the wells in
duplicate for 2 h at 37 °C. Wells were washed with 0.05%
PBST and biotin-conjugated goat anti-Mouse antibody was
applied (Novex Life Technology, cat. no. A16070, 1:10,000
in 2% BSA/PBST) for 45 min at RT followed by
Peroxidase-Avidin (Thermo Fisher Scientific, 1:3500) for
30 min at RT. ABST substrate (Thermo Scientific) was
added to develop the colorimetric reaction. Anti-insulin and
anti-AAV8 antibody titres correlate with absorbances at
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405 nm. Assay and sample control values were deducted
from final measurements.
The frequency of AAV8 capsid- or insulin-specific CD8+
T cells in mouse splenocytes was determined using an IFN-γ
enzyme-linked immunoSpot (ELISPOT) assay (R&D sys-
tems) according to the manufacturer’s instructions. In brief,
plates were blocked with RPMI media prior to loading 2 × 105
freshly isolated splenocytes/well and then stimulated with 50
ng/ml PMA+ 2 μg/ml Ionomycin or 5 μg/ml peptide in
RPMI-1640 (Sigma)+ 2mM L-glutamine (Invitrogen)+ 10%
(v/v) FCS (PAA)+ 1% penicillin/streptomycin+ β-mercap-
toethanol. Peptides (synthesised by Cambridge Research
Biochemicals) were AAV8 capsid-specific NSLANPGIA
[53], C57BL/6 CD8+ T cell insulin-specific SLYQLENYCN,
NOD CD8+ T cell insulin-specific LYLVCGERG. Stimula-
tion was performed for 40 h at 37 °C. Spots were counted
with an Elispot Reader (AID, Strassberg, Germany) with
intensity >10 and size >20.
Soluble IL-10 cytokine production was tested in the
supernatants of splenocytes cultured in RPMI-1640
(Sigma)+ 2mM L-glutamine (Invitrogen)+ 10% (v/v)
FCS (PAA)+ 1% penicillin/streptomycin+ β-mercap-
toethanol with 50 ng/ml PMA+ 2 μg/ml Ionomycin for 48 h
at 37 °C. The amount of IL-10 protein was measured using
a DuoSet® mouse IL-10 ELISA (R&D) according to the
manufacturer’s instructions.
In vivo bioluminescent imaging
Mice injected intravenously with ssAAV8-HLP-Luciferase at
the indicated doses were monitored non-invasively for the
whole-body distribution of the transgene on day 10. Mice
were injected intraperitoneally with 2mg/mouse XenoLight
D-Luciferin (Perkin Elmer, Waltham, USA), anesthetised
with isofluorane and imaged 15min later using the IVIS
Spectrum pre-clinical imaging system (Perkin Elmer, Wal-
tham, USA). The bioluminescence was quantified from ROIs
with deducted background signal using the Living Image 3.2
In Vivo Imaging Software (Perkin Elmer).
Determination of viral genome copy numbers and
insulin transcript levels in the mouse livers and
pancreata
Livers and pancreata extracted from sacrificed mice were
collected in RNAlater (Sigma) for organ preservation and
stored at −20 °C. Total DNA and RNA were isolated using
the All Prep DNA/RNA Mini Kit (Qiagen), according to the
manufacturer’s instructions. Transgene copy number in the
liver was determined using real-time PCR assay using Roto-
Gene 3000 (Corbett Research, Sydney, Australia) and
Rotor-Gene SYBR Green PCR Kit (Qiagen). The primers
were designed against the HLP promoter (forward primer
5′-CAGGACGCTGTGGTTTCTG-3′ and reverse primer
5′-TGCCTGAAGAGAC-3′) and normalised with mouse
GAPDH housekeeping gene (forward primer 5-′TGGA
GAGCCCGCTCAGACCC-3′ and reverse primer 5′-
GGATGGGGTGTCCCTGCGCC-3′) to obtain AAV gen-
ome copy/mouse cell. One microgram of total RNA was
converted to cDNA using random hexamer primers (Inte-
grated DNA Technologies), oligo-dT primers (Integrated
DNA Technologies) and RevertAid™ H Minus Reverse
Transcriptase (Thermo Fisher Scientific) according to the
manufacturer’s protocol. Relative mRNA expression was
quantitated by real-time qPCR. The primers were designed
against the codon optimised human insulin (forward primer
5′-ACTGCTTCCTCTGCTTGCTC-3′ and reverse primer
5′-GCCTCTTTCTCCGCACACAA-3′) or mouse insulin 2
(mINS2) gene (forward primer 5′-CCACAAGTGGCA
CAACTGGA-3′ and reverse primer 5′-ACTGATCTA
CAATGCCACGCT-3′) and normalised against mouse 18S
rRNA (forward primer 5′-CCTGCGGCTTAATTT
GACTC-3′ and reverse primer 5′-CGCTGAGCCAGT
CAGTGTAG-3′). All PCR reactions were performed in
duplicate. The CT of each sample was obtained using
RotorGene version 6.1 software. 2−(ΔΔCT) was calculated
and the relative expression levels were determined by
arbitrarily assigning a value to one to controls.
Passive immunisation
NOD female mice aged 8–30 weeks were injected intra-
venously with either PBS (control) or 5 × 109 vg/mouse
ssAAV2/8-HLP-hINSco and were blood sampled daily for
testing occurrence of anti-AAV8 antibody via ELISA. Sera
were collected 9 days post-injection by terminal cardiac
puncture, pooled and tested for neutralising anti-AAV8
antibodies (see above). To passively immunise the immu-
nocompromised NOD scid, 0.4 ml of this pooled serum was
injected intraperitoneally for 7 consecutive days 4 days after
the beginning of the AAV2/8-HLP-hINSco gene therapy.
CD4+ T cell blockade
Established diabetic NOD female mice were injected
intravenously with 25 × 109 vg/mouse of ssAAV2/8-HLP-
hINSco (d0). Mice received 2 mg of either the IgG2a iso-
type control (MAC219), a non-depleting anti-mouse CD4
mAb (YTS177) as previously described [31] or PBS only
injected 8 h prior to administering gene therapy (intrave-
nously) and on days 1, 7, 9 and 11 (intraperitoneally). The
YTS177 hybridoma was a kind gift from Professor Herman
Waldmann, University of Oxford, and the MAC219
hybridoma was a kind gift from Professor Geoff Butcher,
Babraham Institute. Both antibodies were produced in-
house.
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Immunohistochemistry
Livers and pancreata removed from sacrificed mice were
fixed in 4% PFA for 5 h at 4 °C, dehydrated in 30% sucrose
overnight at 4 °C, and embedded in O.C.T mounting med-
ium (VWR Chemicals) before freezing at −70 °C. Five
micrometre cryostat (Leica) sections were air-dried, fixed in
acetone for 6 min, air-dried, and stored at −20 °C. Immu-
nolabelling was performed on sections pre-blocked with 1%
BSA by incubating with rabbit anti glucagon (Millipore, cat
no. AB932, 1:20) guinea pig anti-insulin (DAKO, cat no.
A0564, 1:150), rabbit anti C-peptide (Cell Signalling, cat
no. 4593S, 1:50), Rat anti-CD3 (Biolegend, cat no. 100202,
1:100), Rat anti-CD8 (Biolegend, cat no. 100702, 1:50) for
1 h at 4 °C. Incubation with relevant Alexa Fluor® second-
ary antibodies (Invitrogen, 1:500) and DAPI (4′,6-diami-
dino-2-phenylindole) (Invitrogen) followed. Sections were
then mounted in Prolong Diamond Antifade solution
(Thermo Fisher Scientific) and visualised using a Zeiss
LSM 700 confocal microscope (Zeiss, Germany). Images
were captured and processed using Zen software (Zeiss).
Mass spectrometry analysis
Seventeen microliters of plasma were extracted with 100 µl
of 80% acetonitrile in water and analysed as previously
described [27].
Mitochondrial activity
T cell oxygen consumption rate (OCR) was measured using
the XF96 Analyzer (Agilent technologies, Santa Clara,
California, USA). In brief, XF96-well plates were coated
using Cell-Tak (BD Biosciences, San Jose, CA, USA) to
allow T cell adhesion. T cells were isolated with the Mouse
CD3+ T cell column enrichment kit (R&D) and plated at the
concentration of 3 × 105 cells/ 50 μl/well, and analysed
using the Mitostress kit (Agilent technologies) according to
the manufacturers’ instructions. Seahorse assay medium
(Agilent technologies) was supplemented with the indicated
glucose concentration, 1 mM glutamine and 1 mM pyr-
uvate. Oligomycin was administered at 1.5 μM, FCCP at 1
μM and rotenone/Antimycin A at 1 μM (all from Agilent
technologies).
Statistical analysis
Statistical differences between experimental groups which
had normal distribution and equal variances were deter-
mined by unpaired Student’s t-test using GraphPad Prism
version 6.0 software (GraphPad, San Diego, CA). Data are
presented as mean ± standard error (SE). Differences in
incidence of diabetes between groups were assessed using
the log-rank survival test. Significant p-values are indicated
with Δ, *(p ≤ 0.05), **(p ≤ 0.01), ***(p ≤ 0.001) or ****(p ≤
0.0001).
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